Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 9 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Celgene Corporation has 10 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 10 actions are handled by 10 distinct examiners, resulting in a unique examiner for every pending case. The portfolio is distributed across 8 distinct art units, which indicates that the 10 distinct examiners are spread across 8 different technical divisions within the USPTO.
The busiest examiner is DAVIS, BRIAN J, who has 1 pending office action. This 1 action represents a portion of the 10 total pending office actions for the company. With 10 distinct examiners and 8 distinct art units, the applicant faces multiple variables in its prosecution landscape. Practitioners must manage 10 different examiner styles across 8 different art units, requiring a strategy that addresses the specific technical standards of each group. The count of 8 art units relative to the 10 pending actions suggests that the Biotechnology & Pharmaceuticals subject matter is technically varied.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (17%) |
| §112 only | 2 (17%) |
| Double-patenting only | 3 (25%) |
| Double-patenting + other | 4 (33%) |
| Multi-statute (no §101) | 1 (8%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 1 | 55.4% | +46.2% |
| DAVIS, BRIAN J | 1 | 84.8% | -4.0% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.9% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
| RAHMANI, NILOOFAR | 1 | 77.5% | -2.9% |
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
| SHUPE, ELIZABETH A | 1 | 66.2% | +44.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18776606 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | DAVIS, BRIAN J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18763757 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | WARD, PAUL V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18800988 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | TCHERKASSKAYA, OLGA V | — |
| 18714760 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CORNET, JEAN P | — |
| 18609867 | TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON | WILSON, MICHAEL C | — |
| 18427510 | COMBINATION THERAPIES USING AN ANTI-BCMA ANTIBODY DRUG CONJUGATE (ADC) IN COMBINATION WITH A GAMMA SECRETASE INHIBITOR (GSI) | PUTTLITZ, KARL J | — |
| 18573790 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BELL, SARA ELIZABETH | — |
| 18563037 | METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPY | METCALF, MATTHEW CURRAN | — |
| 17795829 | ANTI-CD30 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA | SHUPE, ELIZABETH A | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1614 | 1 |
| 1638 | 1 |
| 1642 | 1 |
| 1691 | 1 |
| 1625 | 1 |
| 1643 | 1 |
| 1627 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18800988 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | TCHERKASSKAYA, OLGA V | 1615 | §112DP | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18776606 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | DAVIS, BRIAN J | 1614 | §112DP | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18763757 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | WARD, PAUL V | — | §103§112 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18714760 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CORNET, JEAN P | — | §103 | Non-Final OA | — | Pending | May 30, 2024 |
| 18609867 | TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON | WILSON, MICHAEL C | 1638 | §112 | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18427510 | COMBINATION THERAPIES USING AN ANTI-BCMA ANTIBODY DRUG CONJUGATE (ADC) IN COMBINATION WITH A GAMMA SECRETASE INHIBITOR (GSI) | PUTTLITZ, KARL J | 1642 | DP | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18419894 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAHMANI, NILOOFAR | 1691 | DP | Final Rejection | 14d | Pending | Jan 23, 2024 |
| 18573790 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BELL, SARA ELIZABETH | 1625 | §112 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18563037 | METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPY | METCALF, MATTHEW CURRAN | — | §103DP | Non-Final OA | — | Pending | Nov 21, 2023 |
| 17795829 | ANTI-CD30 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA | SHUPE, ELIZABETH A | 1643 | §103 | Non-Final OA | — | Pending | Jul 27, 2022 |
| 17867294 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | NESTOR, DONNA MICHELLE | 1627 | DP | Non-Final OA | 73d overdue | Pending | Jul 18, 2022 |
| 17620541 | AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME | BERRY, LAYLA D | 1693 | §103DP | Non-Final OA | 48d | Pending | Dec 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial